R&D News | pharmaphorum

News

Takeda plans filings for Sotyktu rival on new psoriasis data

Takeda intends to file for approval of its oral psoriasis therapy zasocitinib next year, with Bristol Myers Squibb's Sotyktu in its sights.

News

As year-end nears, pharma groups plump up their pipelines

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

DBV gets peanut allergy therapy programme back on track

Shares in DBV have shot up on phase 3 results that set up a US filing for its peanut allergy therapy. which could plug a looming hole in the market.

News

Chai raises $130m for AI drug discovery platform

AI specialist Chai Discovery has said it is sitting on a valuation of around $1.3 billion, after raising $130 million in a Series B financing.

News

Kyverna rises on stiff person syndrome data

Kyverna hopes to file CAR-T therapy miv-cell for approval as the first therapy for stiff person syndrome, a rare and debilitating autoimmune disease.

Takeda plans filings for Sotyktu rival on new psoriasis data

As year-end nears, pharma groups plump up their pipelines

Padcev/Keytruda scores again in early bladder cancer

DBV gets peanut allergy therapy programme back on track

Chai raises $130m for AI drug discovery platform

Kyverna rises on stiff person syndrome data

AI, start-ups, and the future of human health: AION Labs’ Ma...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks